Overview

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Injection the day before surgery of 90 mg of Lanreotide LP sub-cutaneously or placebo. Evaluation of the lymphorrhea in the 2 arms of the study
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Limoges
Collaborator:
Ipsen
Treatments:
Angiopeptin
Lanreotide
Somatostatin